Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference
Cocrystal Pharma (Nasdaq: COCP) will present at the Life Science Innovation Northwest 2022 conference on April 20-21, 2022, at the Washington State Convention Center in Seattle.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cocrystal Pharma (Nasdaq: COCP) will present at the Life Science Innovation Northwest 2022 conference on April 20-21, 2022, at the Washington State Convention Center in Seattle. Sam Lee, PhD, President and co-interim CEO, is set to deliver a presentation during the Neuroscience & Pharmaceuticals segment on April 20 at 3:25 PM Pacific. This conference is the Pacific Northwest’s largest annual life science event, aiming to connect investors, researchers, and organizations to discuss significant life science breakthroughs.
Details
News Market Reaction – COCP
The recorded move for COCP in the trading session of this news was -1.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOTHELL, Wash., April 19, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that Sam Lee, PhD, President and co-interim Chief Executive Officer, will present a Company overview at the hybrid in-person and virtual Life Science Innovation Northwest 2022 (LSINW) Conference being held April 20-21, 2022 at the Washington State Convention Center in Seattle. Dr. Lee’s presentation is scheduled during the Neuroscience & Pharmaceuticals segment on Wednesday, April 20 at 3:25 p.m. Pacific time.
About Life Science Innovation Northwest.
Life Science Innovation Northwest (LSINW) is the Pacific Northwest’s largest annual life science conference. This one-and-a-half day event will bring together investors, public and private life science organizations, research institutions, scientists, entrepreneurs, and the global health community to discuss and feature some of the most compelling life science breakthroughs of our time. More information is available here.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.
Investor Contact:
LHA Investor Relations
Jody Cain
310-691-7100
jcain@lhai.com
Media Contact:
JQA Partners
Jules Abraham
917-885-7378
Jabraham@jqapartners.com
# # #
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.